MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that results from the Phase 1 Clinical Trial undertaken by MMJ's wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Ltd have been published.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that TSX-V listed Harvest One Cannabis Inc. (CVE:HVST), which is 59% owned by MMJ, has released an operational update on its medical and health division Satipharm AG.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to advise that it has agreed to invest A$500,000 in ASX listed Israeli life sciences company eSense-Lab Limited (ASX:ESE).
A significant milestone has now been reached in Australia that has a major positive impact on the potential business, cashflow and profitability for Queensland Bauxite Limited's (ASX:QBL) investment in Medical Cannabis Limited.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to provide its quarterly activities report for the period ended 30 September 2017, together with its Appendix 4C.
During the September Quarter 2017, Queensland Bauxite Limited (ASX:QBL) continued to press to progress the development of its flagship South Johnstone DSO bauxite project in northern Queensland, with the Company aiming to generate positive net cash flows in the short term through the commencement of DSO bauxite production and shipping.
MMJ PhytoTech Ltd (ASX:MMJ) provides the Company's 2017 Annual Report to shareholders.
